Effect of F-18 Fluorodeoxyglucose Uptake by Bone Marrow on the Prognosis of Head and Neck Squamous Cell Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeong Won | - |
dc.contributor.author | Ban, Myung Jin | - |
dc.contributor.author | Park, Jae Hong | - |
dc.contributor.author | Lee, Sang Mi | - |
dc.date.accessioned | 2021-08-11T09:24:49Z | - |
dc.date.available | 2021-08-11T09:24:49Z | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4330 | - |
dc.description.abstract | The purpose of this study was to assess the relationship between F-18 fluorodeoxyglucose (FDG) uptake in bone marrow (BM) on positron emission tomography/computed tomography (PET/CT) and survival in patients with head and neck squamous cell carcinoma (HNSCC). We retrospectively enrolled 157 HNSCC patients who underwent staging FDG PET/CT and subsequent treatment. On PET/CT, primary tumor metabolic characteristics, mean FDG uptake of BM (BM SUV), and BM-to-liver uptake ratio (BLR) were measured. The prognostic significance of FDG uptake of BM for predicting disease progression-free survival and distant failure-free survival was assessed using a Cox proportional hazards regression model. In univariate analysis for disease progression-free survival, increased BM SUV and BLR were associated with poor survival. In multivariate analysis, BLR (p = 0.044; hazard ratio, 1.96), TNM stage (p = 0.014; hazard ratio, 2.87) and maximum FDG uptake of the primary tumor (p = 0.046; hazard ratio, 2.38) were independently associated with disease progression-free survival. For distant failure-free survival, BLR, TNM stage, tumor size, and metabolic parameters of the primary tumor showed prognostic significance in univariate analysis. However, none of the variables showed significance in multivariate analysis. FDG uptake of BM in HNSCC patients might be a significant predictor for disease progression-free survival. Further studies with large patient population are needed to validate the results. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Effect of F-18 Fluorodeoxyglucose Uptake by Bone Marrow on the Prognosis of Head and Neck Squamous Cell Carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/jcm8081169 | - |
dc.identifier.wosid | 000483737700107 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.8, no.8 | - |
dc.citation.title | Journal of Clinical Medicine | - |
dc.citation.volume | 8 | - |
dc.citation.number | 8 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | TO-LYMPHOCYTE RATIO | - |
dc.subject.keywordPlus | FDG UPTAKE | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | F-18-FLUORODEOXYGLUCOSE UPTAKE | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | PET/CT | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | TOMOGRAPHY | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | PARAMETERS | - |
dc.subject.keywordAuthor | head and neck cancer | - |
dc.subject.keywordAuthor | fluorodeoxyglucose F-18 | - |
dc.subject.keywordAuthor | positron emission tomography | - |
dc.subject.keywordAuthor | bone marrow | - |
dc.subject.keywordAuthor | prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.